API | alglucerase

alglucerase (ceredase) Report issue

Biologics Recombinant protein Orphan Drug ^FDA Approved ^FDA Priority Review ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH repoDB

Active Ingredient History

NOW

Alglucerase was a biopharmaceutical drug for the treatment of Gaucher's disease. It was a modified form of human β-glucocerebrosidase enzyme, where the non-reducing ends of the oligosaccharide chains have been terminated with mannose residues. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecule:
alglucerase

More Chemistry

Pharmacology

Mechanisms of Action:
Multi-specific: No
Black Box: No
Availability: Discontinued
Delivery Methods: Parenteral
Pro Drug: No

alglucerase | ceredase | human glucocerebrosidase

Organizations (3)

Research & Development (2)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (1)

Approved Indications (1)

Gaucher Disease

Experimental Indications - Clinical Trial Phases 1-4 (1)

Gaucher Disease (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 2
# of Trial Organizations: 2

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue